Management of Mild to Moderate NSIP in Anti-Synthetase Syndrome

Introduction and Induction Phase

The European Society for Medical Oncology recommends starting with prednisone 1 mg/kg/day (typically 60-80 mg/day) and mycophénolate mofétil (Cellcept) 1000-1500 mg twice a day for mild to moderate NSIP in anti-synthetase syndrome, with a gradual tapering of prednisone over 4-6 weeks to 10 mg/day, followed by a slow reduction of 1 mg every 4 weeks, while maintaining Cellcept for at least 6-12 months 1, 2
The initial dose of prednisone is 1 mg/kg/day orally (generally 60-80 mg/day for an adult), which corresponds to the recommended dose for autoimmune interstitial pneumonias of grade 1-2, as suggested by the Annals of Oncology 3, 4, 1
The high-dose period should be maintained for 2-4 weeks until clinical and radiological improvement is documented, according to Praxis Medical Insights 1, 2

The rapid tapering phase over 4-6 weeks is in line with the ESMO recommendations for interstitial pneumonias of grade 1-2, with a reduction to 10 mg/day and maintenance, as recommended by Praxis Medical Insights 1, 2, 3, 4
After 6 weeks, a slow tapering of 1 mg every 4 weeks should be pursued until the minimum effective maintenance dose is reached, typically 5-10 mg/day, as suggested by Praxis Medical Insights 2
The total duration of tapering usually takes a minimum of 4-6 months for mild to moderate cases, according to the Annals of Oncology and Praxis Medical Insights 3, 1

Cellcept should be maintained at a full dose (1000 mg twice a day) for at least 6-12 months after achieving clinical and radiological remission, serving as a corticosteroid-sparing agent and background treatment to prevent relapses, as recommended by the Annals of Oncology 3, 4
Unlike prednisone, Cellcept generally does not require gradual tapering and can be maintained at a stable dose throughout the treatment period, according to the Annals of Oncology 3, 4

During the rapid tapering phase (weeks 1-6), clinical evaluation should be performed every 2-4 weeks, monitoring respiratory symptoms, oxygen saturation, and functional status, as recommended by Praxis Medical Insights 1, 2
After 6 weeks, monthly surveillance should be continued during the slow reduction phase, with functional respiratory tests at 10 mg of prednisone and periodically during maintenance tapering, as suggested by Praxis Medical Insights 2

Prophylaxis against Pneumocystis jiroveci pneumonia (PCP) should be initiated if prednisone is ≥20 mg for ≥4 weeks and continued as long as this condition is met, according to the Annals of Oncology and Praxis Medical Insights 5, 1, 2
Gastrointestinal protection with a proton pump inhibitor (PPI) is recommended for all patients receiving corticosteroids for grade 2-4 pneumopathy, as suggested by the Annals of Oncology and Praxis Medical Insights 5, 1, 2
Calcium and vitamin D supplementation should be started at the beginning of prolonged corticosteroid treatment, according to the Annals of Oncology and Praxis Medical Insights 5, 1, 2

In case of relapse during tapering, prednisone should be immediately increased to the pre-relapse dose and maintained for 4-8 weeks until stabilization, then tapering should be resumed at half the previous rate, as recommended by Praxis Medical Insights 2
The adequacy of background immunosuppression (Cellcept) should be reassessed, and the addition of another agent like rituximab should be considered if multiple relapses occur, according to Praxis Medical Insights 2